Anti-VEGF 165b Antibody, clone 56/1

Evaluated by Western Blotting in NIH/3T3 cell lysate.

Western Blotting Analysis: 2 µg/mL of this antibody detected VEGF 165b in 10 µg of NIH/3T3 cell lysate.

Research Category
Apoptosis & Cancer

Research Sub Category
Apoptosis - Additional

This Anti-VEGF 165b Antibody, clone 56/1 is validated for use in Western Blotting and Immunohistochemistry and ELISA for the detection of VEGF 165b.

Western Blotting Analysis: 2 µg/mL of a representative lot of this antibody detected VEGF 165b in 10 µg of PC12 cell lysate.

Immunohistochemistry Analysis: A 1:50 dilution of a representative lot detected detected VEGF 165b in tumor cells of human prostate cancer tissue.

Western Blotting Analysis: A representative lot detected recombinant VEGF 165b protein (Woolard, J., et al. (2004) CANCER RESEARCH 64:7822–7835).

Western Blotting Analysis: A representative lot detected VEGF 165b in human eye tissue lysate (Perrin, R.M., et al. (2005) Diabetologia. 48: 2422–2427).

Immunohistochemistry Analysis: A representative lot detected VEGF 165b in Mouse mesentery tissue (Woolard, J., et al. (2004) CANCER RESEARCH 64:7822–7835).

Immunohistochemistry Analysis: A representative lot detected VEGF 165b in tumor tissue sections (Peiris-Pagès, M., et al. (2010) Pathol. 222(2): 138–147).

ELISA: A representative lot of this antibody detected VEGF 165b by ELISA on tumor tissue samples & tumor cell lines (Peiris-Pagès, M., et al. (2010) Pathol. 222(2): 138–147).

ELISA: A representative lot of this antibody detected VEGF 165b by ELISA on recombinant protein VEGF 165b (Woolard, J., et al. (2004) CANCER RESEARCH 64:7822–7835).

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

VEGF (Vascular endothelial growth factor, VEGFA, VEGF-A), a dimeric ligand, is among the most potent angiogenic mitogens. VEGF is secreted by tumor cells and other cells exposed to hypoxia. VEGF is a highly specific mitogen for vascular endothelial cells. Seven VEGF isoforms (a, b, c, d, e, f, g) are generated as a result of alternative splicing from a single VEGF gene. The most commonly studied isoforms are VEGF121, VEGF165, and VEGF189 (f, d and b, respectively) All seven isoforms differ in their molecular mass and in biological properties such as their ability to bind to cell-surface heparan-sulfate proteoglycans. The expression of VEGF is potentiated and is secreted by tumor cells in response to hypoxia, by activated oncogenes, and by a variety of cytokines. VEGF induces angiogenesis as well as permeabilization of blood vessels, and plays a central role in the regulation of vasculogenesis. VEGF expression correlates to the degree of tumor vascularization and with increased metastatic risk. Additionally, VEGF induces endothelial cell proliferation, promotes cell migration, and inhibits apoptosis. Consequently, inhibition of VEGF signaling abrogates the development of a wide variety of tumors.

~ 22 kDa observed.
Additional uncharacterized bands may be visible in some lysates.

Epitope: C-terminus

KLH-conjugated linear peptide corresponding to the C-terminus of Mouse VEGF 165b.

Format: Purified

Protein G Purified

Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.